Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.100
-0.020 (-0.94%)
At close: Sep 8, 2026, 4:00 PM EDT
2.100
0.00 (0.00%)
After-hours: Sep 8, 2026, 4:15 PM EDT
BDTX Revenue
In the year 2025, Black Diamond Therapeutics had annual revenue of $70.00M.
Revenue (ttm)
$70.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
120.65M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Coya Therapeutics | 8.02M |
| Rani Therapeutics Holdings | 4.88M |
| Cibus | 4.35M |
| Connect Biopharma Holdings | 2.95M |
| NeOnc Technologies Holdings | 39.99K |
BDTX News
- 6 days ago - Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - Raymond James keeps Outperform rating on Black Diamond Therapeutics after Q2 - TheFly
- 4 weeks ago - Black Diamond Therapeutics setup ‘attractive,’ says Jefferies - TheFly
- 4 weeks ago - Black Diamond Therapeutics reports Q2 EPS (17c), consensus (20c) - TheFly
- 4 weeks ago - Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Black Diamond Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Black Diamond Therapeutics Earnings release: Q2 2026 - Filings
- 2 months ago - Black Diamond Therapeutics Transcript: AGM 2026 - Transcripts